Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation in Early Breast Cancer After Breast-conserving Surgery

  • End date
    Dec 31, 2026
  • participants needed
  • sponsor
    Instituto Brasileiro de Controle do Cancer
Updated on 18 March 2021


Radiotherapy has been confirmed as an important treatment breast-conserving surgery reducing the risk of any recurrence of breast cancer and breast cancer-related mortality in patients with early breast cancer.

There are no comparative data on the ideal radiotherapy treatment regimen for patients with early stage breast cancer who underwent conservative surgery in the Brazilian population.


The investigators propose a prospective, randomized, pilot study, with active control, to evaluate the viability and safety of accelerated partial breast irradiation, in 5 fractions, comparing with the radiotherapy regimens of the whole breast in 15 and 5 fractions, in patients with breast cancer, in initial stage, who underwent conservative surgery.

Condition Breast Cancer, Breast Cancer, cancer, breast
Treatment Active Comparator: Standard, Experimental 1: Hypofractionated radiotherapy, Experimental 2: Accelerated Partial Breast Irradiation
Clinical Study IdentifierNCT04669873
SponsorInstituto Brasileiro de Controle do Cancer
Last Modified on18 March 2021


Yes No Not Sure

Inclusion Criteria

Information to the patient and signed informed consent
Women aged 50 years
Breast conserving surgery
Pathologic tumor size < 3 cm (maximum microscopic diameter of the invasive component)
Invasive adenocarcinoma (except classic invasive lobular carcinoma)
Unifocal disease
Histopathologic grades I or II
Eastern Cooperative Oncology Group (ECOG) 0-1
Lymphovascular invasion absent
Negative axillary lymph nodes
Minimum microscopic margins of non-cancerous tissue of 2mm (excluding deep margin when in deep fascia)
No prior breast or mediastinal radiotherapy
No hematogenous metastases

Exclusion Criteria

Previous malignancy (except non-melanomatous skin cancer)
Classical-Type Invasive Lobular Carcinoma
Neoadjuvant chemotherapy
Human Epidermal growth factor Receptor-type 2 positive (HER2+)
Triple-negative breast cancers
Intravascular lymphoma present
Contraindications to radiotherapy
No geographical, social or psychologic reasons that would prevent study follow
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note